BRAF and hepatocellular carcinoma: 8 However, BRAFV600E and other classes of BRAF alterations and their clinical implications have not been broadly assessed in other gastrointestinal (GI) malignancies, including pancreatic cancer (PDAC), gastric/gastroesophageal cancer (GEA), hepatocellular carcinoma (HCC), and cholangiocarcinoma (CCA).14